Home / Business and Economy / AGAMREE drives Santhera's revenue surge
AGAMREE drives Santhera's revenue surge
29 Apr
Summary
- AGAMREE sales nearly doubled revenues in 2025.
- Global partnerships expanded patient access worldwide.
- Company anticipates cash flow breakeven in Q3 2026.
Santhera Pharmaceuticals reported a robust 2025 fiscal year, highlighted by a 97% increase in total revenue to CHF 77.2 million. This significant growth was primarily driven by the strong commercial momentum of AGAMREE, its treatment for Duchenne muscular dystrophy (DMD).
The company detailed AGAMREE's rapid adoption across core European markets, with Germany and Austria showing substantial market shares. Following its Q2 2025 launch, the UK also demonstrated encouraging early uptake.
Global expansion was a key theme, with strategic partnerships significantly broadening patient access. Collaborations with Catalyst Pharmaceuticals in North America and Sperogenix in China continued to drive revenue and reach. Furthermore, a January 2026 licensing agreement with Nxera Pharma for Japan and key Asia-Pacific markets expanded Santhera's global footprint.
Long-term clinical data, extending up to eight years, reinforced AGAMREE's differentiated profile, showcasing sustained efficacy comparable to standard-of-care corticosteroids with an improved safety profile. This reinforced its positioning as a long-term treatment option.
Financially, Santhera reported product sales of CHF 25.8 million and CHF 23.1 million in royalties and milestones. The company expects to reach cash flow breakeven in Q3 2026, with no additional funding anticipated, positioning it for continued value delivery.
